CRBP
insider transactionsCorbus Pharmaceuticals Holdings, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-27.0K
13.5K buy · 40.5K sell
Net value · 365d
-$219.4K
$101.2K in · $320.6K out
Sentiment · 365d
Net selling
24% buying · 76% selling
Open-market trades · 365d
11
13.5K buy · 40.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director · 10b5-1
$16.0K
2.0K sh · $7.91
Own -14%
-
Sell·S
Director · 10b5-1
$38.0K
4.8K sh · $7.91
Own -56%
-
Sell·S
Director · 10b5-1
$19.1K
2.4K sh · $7.91
Own -24%
-
Buy·P
Chief Business Officer
$68.2K
9.0K sh · $7.58
Own +14%
-
Buy·P
Chief Business Officer
$33.0K
4.5K sh · $7.33
Own +7%
-
Grant·A
Chief Business Officer
$0
192.3K sh
Own New
-
Grant·A
Chief Business Officer
$0
58.3K sh
Own +1666%
-
Grant·A
Director
$0
12.3K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own +37%
-
Grant·A
Director
$0
12.3K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own +50%
-
Grant·A
Director
$0
12.3K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own +79%
-
Grant·A
Director
$0
24.7K sh
Own New
-
Grant·A
Director
$0
7.5K sh
Own New
-
Grant·A
Director
$0
12.3K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own +61%
-
Sell·S
Chief Medical Officer
$50.6K
6.1K sh · $8.30
Own -6%
-
Sell·S
Chief Operating Officer
$6.3K
847 sh · $7.38
Own -2%
-
Sell·S
Sean F. Moran KEY
Chief Financial Officer · 10b5-1
$36.6K
4.7K sh · $7.78
Own -5%
-
Sell·S
Yuval Cohen KEY
Chief Executive Officer · 10b5-1
$108.0K
13.9K sh · $7.78
Own -7%
-
Sell·S
Chief Medical Officer
$26.6K
3.3K sh · $8.09
Own -3%
-
Sell·S
Chief Operating Officer
$19.5K
2.4K sh · $8.09
Own -4%
-
Grant·A
Chief Operating Officer
$0
85.1K sh
Own New
-
Grant·A
Chief Operating Officer
$0
28.4K sh
Own +109%
-
Grant·A
Chief Medical Officer
$0
85.1K sh
Own New
-
Grant·A
Chief Medical Officer
$0
28.4K sh
Own +40%
-
Grant·A
Sean F. Moran KEY
Chief Financial Officer
$0
84.2K sh
Own New
-
Grant·A
Sean F. Moran KEY
Chief Financial Officer
$0
28.1K sh
Own +38%
-
Grant·A
Yuval Cohen KEY
Chief Executive Officer
$0
150.0K sh
Own New
-
Grant·A
Yuval Cohen KEY
Chief Executive Officer
$0
50.0K sh
Own +36%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Winston Kung 10b5-1 | Sell S | 2.0K | $16.0K |
| Jun 10, 2026 | John Kenneth Jenkins 10b5-1 | Sell S | 4.8K | $38.0K |
| Jun 10, 2026 | Anne Altmeyer 10b5-1 | Sell S | 2.4K | $19.1K |
| Jun 3, 2026 | Nishant C Saxena | Buy P | 9.0K | $68.2K |
| Jun 2, 2026 | Nishant C Saxena | Buy P | 4.5K | $33.0K |
| May 21, 2026 | Nishant C Saxena | Grant A | 192.3K | $0 |
| May 21, 2026 | Nishant C Saxena | Grant A | 58.3K | $0 |
| May 19, 2026 | Winston Kung | Grant A | 12.3K | $0 |
| May 19, 2026 | Winston Kung | Grant A | 3.8K | $0 |
| May 19, 2026 | Rachelle Suzanne Jacques | Grant A | 12.3K | $0 |
| May 19, 2026 | Rachelle Suzanne Jacques | Grant A | 3.8K | $0 |
| May 19, 2026 | John Kenneth Jenkins | Grant A | 12.3K | $0 |
| May 19, 2026 | John Kenneth Jenkins | Grant A | 3.8K | $0 |
| May 19, 2026 | Brent Pfeiffenberger | Grant A | 24.7K | $0 |
| May 19, 2026 | Brent Pfeiffenberger | Grant A | 7.5K | $0 |
| May 19, 2026 | Anne Altmeyer | Grant A | 12.3K | $0 |
| May 19, 2026 | Anne Altmeyer | Grant A | 3.8K | $0 |
| Mar 2, 2026 | Dominic Smethurst | Sell S | 6.1K | $50.6K |
| Feb 17, 2026 | Ian Hodgson | Sell S | 847 | $6.3K |
| Feb 13, 2026 | Sean F. Moran KEY 10b5-1 | Sell S | 4.7K | $36.6K |
| Feb 13, 2026 | Yuval Cohen KEY 10b5-1 | Sell S | 13.9K | $108.0K |
| Feb 3, 2026 | Dominic Smethurst | Sell S | 3.3K | $26.6K |
| Feb 3, 2026 | Ian Hodgson | Sell S | 2.4K | $19.5K |
| Jan 14, 2026 | Ian Hodgson | Grant A | 85.1K | $0 |
| Jan 14, 2026 | Ian Hodgson | Grant A | 28.4K | $0 |
| Jan 14, 2026 | Dominic Smethurst | Grant A | 85.1K | $0 |
| Jan 14, 2026 | Dominic Smethurst | Grant A | 28.4K | $0 |
| Jan 14, 2026 | Sean F. Moran KEY | Grant A | 84.2K | $0 |
| Jan 14, 2026 | Sean F. Moran KEY | Grant A | 28.1K | $0 |
| Jan 14, 2026 | Yuval Cohen KEY | Grant A | 150.0K | $0 |
| Jan 14, 2026 | Yuval Cohen KEY | Grant A | 50.0K | $0 |
About CRBP insider trading
This page tracks insider transactions for Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.